ADM unveils supportive solutions for GLP-1 users

ADM has introduced a supportive solutions platform for consumers using GLP-1 and other anti-obesity medications (AOMs). GLP-1 receptor agonists, known by brand names such as Ozempic, Wegovy and Mounjaro, help manage blood sugar levels and suppress appetite.

This new platform is based on proprietary consumer insights and in-depth scientific research. It features over 25 market-ready concepts for food, beverage and dietary supplement manufacturers, aimed at assisting consumers on their weight management journeys. The use of AOMs has surged recently, with Goldman Sachs Research projecting the global market could reach £100 billion by 2030. This growth has created a distinct segment of consumers with specific nutritional needs, as highlighted by a survey showing that 83 percent find food products more appealing when marketed as supportive of those on GLP-1 medications.

Dietary changes in GLP-1 users

Since starting GLP-1 treatments, 78 percent of consumers report feeling full more quickly, impacting their eating habits. Many are snacking less during the mid-morning (53 percent), mid-afternoon (50 percent), and late-night (46 percent). Additionally, 74 percent are more open to trying new foods, while 64 percent report a decrease in cravings for sweet foods. Notably, 83 percent of consumers have started cooking more at home. Factors such as nutrition (64 percent), taste (64 percent) and portion size (60 percent) have also become more important when purchasing food and beverages.

The ADM platform leverages a range of functional ingredients, including plant-based proteins, prebiotic fibre and probiotics, to address the emerging demand for tailored nutrition support. The platform targets five key needs during and after AOM usage:

• Maintaining Muscle Mass: 20-40 percent of weight loss can come from muscle mass, and plant-based proteins can help support lean muscle.

• Minimising Gastrointestinal Discomfort: Common concerns among AOM users include gastrointestinal symptoms. The platform includes prebiotic fibre and probiotics to support gut health.

• Supporting Hydration: Research indicates that 44 percent of consumers taking GLP-1 products often feel less hydrated. Ingredients like coconut water powder can help address this issue.

• Promoting Satiety: AOMs can reduce ‘food noise,’ which may return when discontinuing treatment. The platform offers dietary solutions to help manage satiety.

• Managing Weight Regain: To assist with weight management after discontinuation of AOMs, the platform provides ingredients that support metabolic health and satiety.

Overall, ADM aims to meet the unique dietary needs of consumers using AOMs, offering solutions that align with their evolving nutritional preferences. When shifting to a caloric deficit on a GLP-1 supported regimen, a focus on the content of the calorie intake is vital. A trend towards thoughtful supplementation represents a huge positive step in such a rapidly growing market.

For more information on ADM’s new platform and its GLP-1 complementary nutrition concepts, visit here.